Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors
Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Jeffrey G. Supko(Harvard University), Howard Safran(Brown University), Nadia Salem(Sigma-Tau Pharmaceuticals (United States)), Silvia Pace(Sigma Tau (Italy)), Nela Zvereva(Harvard University), Thomas J. Lynch(Nationwide Children's Hospital), David P. Ryan(East Carolina University), Neal Ready(Duke University), Jeffrey W. Clark(Massachusetts General Hospital), Xiaoying He(Shanxi Medical University), Antonino Amato(Sigma-Tau Pharmaceuticals (United States))
Cited by 27
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k